Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ada H. C. Kung"'
Publikováno v:
Clinical Immunology. 92:138-152
A human sequence IgGkappa anti-CD4 monoclonal antibody (mAb), HM6G, originally isolated from a human immunoglobulin transgenic mouse was specific for and bound with high binding avidity to the CD4 antigen expressed on human, chimpanzee, and cynomolgu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30c7e412dac3fb6db6d74cf1c316e9c
https://doi.org/10.1006/clim.1999.4734
https://doi.org/10.1006/clim.1999.4734
Publikováno v:
Pharmaceutical Research. 14:224-229
Purpose. The pharmacokinetics of rBPI23, a recombinant amino terminal fragment of bactericidal/permeability-increasing protein that binds to and neutralizes endotoxin, was investigated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f7b153d375d51e8a2fa534b7b1d9865
https://doi.org/10.1023/a:1012013113759
https://doi.org/10.1023/a:1012013113759
Autor:
Susan L. Bernhard, Robert J. Bauer, Maria Fang, Scott D. Leigh, Ken Der, Nneka Ottah Ihejeto, Ada H. C. Kung, Stephen F. Carroll, Cynthia A. Birr
Publikováno v:
Biopharmaceutics & Drug Disposition. 17:761-774
The pharmacokinetics of several proteins were investigated using two different assays. A 23kDa recombinant protein fragment of bactericidal/permeability-increasing protein (rBPI 23 ) was radiolabeled with 125 I using Iodo-beads® and administered to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d6658a7cf86f0772c740a3c7aae43e0
https://doi.org/10.1002/(sici)1099-081x(199612)17:9<761::aid-bdd992>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199612)17:9<761::aid-bdd992>3.0.co
Autor:
Narsingh D. Agnish, Judith W. Henck, Ada H. C. Kung, Mercedes Serabian, Kim G. Hilbish, Andrew G Hendrickx, Joyce Mordenti, Joy A. Cavagnaro
Publikováno v:
Teratology. 53:185-195
Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105 (J.WH.); Miles, Inc., Elkhart, Indiana 46515 (K.G.H.); USFDA, Rockville, Maryland 20852 (M.A.S., J.A.C.); California Regional Primate Research Center, Davis, California 95616 (A.G.H.); Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afd391ebeb6a7cec52fe46bbff7cb9a9
https://doi.org/10.1002/(sici)1096-9926(199603)53:3<185::aid-tera6>3.0.co
https://doi.org/10.1002/(sici)1096-9926(199603)53:3<185::aid-tera6>3.0.co
Autor:
Scott D. Leigh, Robert J. Bauer, Ada H. C. Kung, Dianne M. Fishwild, Susan L. Bernhard, Stephen F. Carroll, Marc D. Better, Robert E. Williams
Publikováno v:
Journal of Biological Chemistry. 270:14951-14957
Fusion proteins between cell-targeting domains and cytotoxic proteins should be particularly effective therapeutic reagents. We constructed a family of immunofusion proteins linking humanized Fab, F(ab')2, or single chain antibody forms of the H65 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e147e908f26a5c1b0d7acb8d20cd8223
https://doi.org/10.1074/jbc.270.25.14951
https://doi.org/10.1074/jbc.270.25.14951
Publikováno v:
Journal of the American College of Toxicology. 13:64-75
The immunoconjugate, XomaZyme-CD5 Plus, consists of a murine immunoglobulin IgGl monoclonal antibody directed against the CD5 antigen present on mature human T lymphocytes and ricin A chain (RTA), a potent ribosomal inhibitory protein. XomaZyme-CD5 P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5366d44d28e5d8748b9fdc5949478d0
https://doi.org/10.3109/10915819409140656
https://doi.org/10.3109/10915819409140656
Publikováno v:
International Journal of Immunopharmacology. 15:871-878
A human peripheral blood lymphocyte-reconstituted severe combined immunodeficient (hu-PBL-SCID) mouse model was used to compare in vivo efficacy of immunoconjugates directed against the CD5 antigen present on human T-cells. Four anti-CD5 immunoconjug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c82f65f1390f8a4dcf695aa61ba459fe
https://doi.org/10.1016/0192-0561(93)90004-i
https://doi.org/10.1016/0192-0561(93)90004-i
Autor:
Albert Cohen, Ada H. C. Kung, Willem N.m. Hustinx, Mark L. White, Betty J. Nelson, Nancy Wedel, Nadav Friedmann, Robert J. Bauer
Publikováno v:
Shock (Augusta, Ga.). 5(2)
A phase I pharmacokinetic and safety clinical trial of rBPI23, a recombinant amino terminal fragment of bactericidal/permeability-increasing protein, was conducted in healthy male volunteers. rBPI23 was administered as a 5 or 30 min infusion at doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6faca0b6085c120a72eb1fe297fda4
https://pubmed.ncbi.nlm.nih.gov/8705395
https://pubmed.ncbi.nlm.nih.gov/8705395
Autor:
Stephen F. Carroll, Dane Goff, Susan L. Bernhard, Ada H. C. Kung, Will Leach, Robert J. Bauer
Publikováno v:
Bioconjugate chemistry. 5(3)
Substituted 2-iminothiolanes (X2ITs) are new heterobifunctional crosslinking agents designed for the preparation of disulfide-linked conjugates with enhanced resistance to reduction. Based upon 2-IT substituted at the 4 and/or 5 position, these reage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b669a287acbaa7282deab69308f6c2c0
https://pubmed.ncbi.nlm.nih.gov/7918744
https://pubmed.ncbi.nlm.nih.gov/7918744
Publikováno v:
International journal of immunopharmacology. 15(6)
Severe combined immunodeficient mice reconstituted with human peripheral blooldlymphocytes (hu-PBL-SCID mice) were used to evaluate in vivo efficacy of a mouse IgG1 monoclonal antibody (mAb)-ricin toxin A chain immunoconjugate (H65-RTA) directed agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1e4c53bf8b1617fbc05ee92fff48ee6
https://pubmed.ncbi.nlm.nih.gov/7691766
https://pubmed.ncbi.nlm.nih.gov/7691766